Company to attend upcoming NewYorkBIO Innovation Summit on September 30, 2025, in New York City NEW YORK CITY, NY / ACCESS ...
The deubiquitinase USP17LA negatively regulates T-cell activation and attenuates anti-tumor immunity
USP17LA loss enhances T-cell function and anti-tumor activity in murine tumor models. Usp17la-deficient T cells exhibit ...
ReCode Therapeutics, a clinical-stage genetic medicines company using tissue-specific delivery to power the next wave of mRNA ...
The Brighterside of News on MSN
UCLA scientists use light to create energy-efficient generative AI models
Artificial intelligence has dazzled the world with its ability to create pictures, words, and even music from scratch. But ...
German manufacturers Plisch and RFmondial have produced a VHF Band III DRM transmitter, which the companies said is the first ...
Vertex faces pressure from potential U.S. drug pricing reforms and tariffs. Click here to find out why VRTX stock is a Hold.
Homer Dudley, an American engineer and scientist, may have always wanted to make his mark on the technological world but didn ...
In this interview, Technology Networks spoke with Gene Mack, chief executive officer and president of Gain Therapeutics, to ...
Pulled from a shuttered abandoned dealership, this high-end wagon hides a potent Super Marauder 390 V8 under its desert-baked skin ...
US pharma major Bristol Myers Squibb has announced that the Phase III EXCALIBER-RRMM study evaluating iberdomide, an ...
Madeline Verbeke, Senior Clinical Advisor, MMIT, touches on injectable and oral GLP-1's impact on the clinical landscape, and ...
Iberdomide, which is being positioned as a successor to Revlimid, will continue in EXCALIBER-RRMM as the study progresses to ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback